Imatinib (Gleevec) as a paradigm of targeted cancer therapies
- PMID: 20375651
- DOI: 10.2302/kjm.59.1
Imatinib (Gleevec) as a paradigm of targeted cancer therapies
Similar articles
-
Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.J Clin Invest. 2011 Apr;121(4):1227-8. doi: 10.1172/jci57942. J Clin Invest. 2011. PMID: 21630503 Free PMC article. No abstract available.
-
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.J Hematother Stem Cell Res. 2001 Dec;10(6):721-4. doi: 10.1089/152581601317210818. J Hematother Stem Cell Res. 2001. PMID: 11798498 No abstract available.
-
[Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].Medicina (B Aires). 2010;70(3):293-6. Medicina (B Aires). 2010. PMID: 20529782 Spanish. No abstract available.
-
Treatment for chronic myelogenous leukemia: the long road to imatinib.J Clin Invest. 2007 Aug;117(8):2036-43. doi: 10.1172/JCI31691. J Clin Invest. 2007. PMID: 17671637 Free PMC article. Review.
-
Translation of the Philadelphia chromosome into therapy for CML.Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958. Blood. 2008. PMID: 19064740 Review.
Cited by
-
Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.J Drug Target. 2018 Jun-Jul;26(5-6):435-447. doi: 10.1080/1061186X.2017.1419363. Epub 2018 Jan 10. J Drug Target. 2018. PMID: 29285948 Free PMC article. Review.
-
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.Front Oncol. 2016 Jul 15;6:152. doi: 10.3389/fonc.2016.00152. eCollection 2016. Front Oncol. 2016. PMID: 27471678 Free PMC article. Review.